NOTES TO THE CONSOLIDATED FINANCIALSTATEMENTS Continued 38.
SUBSIDIARIES The main subsidiaries of Hikma Pharmaceuticals PLC are as follows: Ownership% Ownership% Ordinary shares Ordinary shares At 31 December At 31 December Companys name Established in 2012 2011 Hikma Pharmaceuticals Limited Jordan 100 100 Arab Pharmaceutical Manufacturing Co. Jordan 100 100 Hi h lLAl kma P arma A geria SAR geria 100 100 Hikma Farmaceutica S. A. Portugal 100 100 West-Ward Pharmaceutical Corp. U. S. A.
100 100 Pharma Ixir Co. Ltd Sudan 51 51 Hikma Pharma SAE Egypt 100 100 Thymoorgan Pharmazie GmbHGermany 100 100 Hi ha mHGe kma P rma G b rmany 100 100 Hikma Italia S. P. A Italy 100 100 Al Jazeera Pharmaceutical Industries Ltd. K. S. A.
100 100 Societe DIndustries Pharmaceutiques Ibn Al Baytar S. A. Tunisia 66 66 SPA Societe Al Dar Al Arabia Algeria 100 100 Societe fide Promotion Pharmaceutique du Maghreb S. A. Morocco 94.1 84.3 Savanna Pharmaceuticals Industries Co. Ltd. Sudan 100 100 39.
DEFINED CONTRIBUTION RETIREMENT BENEFIT PLAN Hikma Pharmaceuticals PLC has dened contribution retirement plans in three of its subsidiaries: West-Ward Pharmaceuticals Corp, HikmaPharmaceuticals Limited Jordan and Arab Pharmaceutical Manufacturing Co.
The details of each contribution plan are as follows: Hikma Pharmaceuticals Limited Jordan: The Group currently has an employee savings plan wherein the Group fully matches employees contributions, which are xed at 10% upto2011 was 5% of salary.
Employees are entitled to 30% of the Group contributions after three years of employment with the Group andanadditional 10% for each subsequent year.
Employees fully vest in the Group contributions after ten years of employment.
The Groups contributions for the year ended 31 December 2012 were $2,163,000 2011: $885,000.
West-Ward Pharmaceuticals Corp: 401 k salary saving plan Prior to 2001, West-Ward Pharmaceutical Corp established a 401 k dened contribution plan, which allows all eligible employees to defer a portion of their income through contributions to the plan.
All employees not covered by any collective bargaining agreement are eligible after being employed for one year.
Employees can defer up to 95% of their gross salary into the plan, not to exceed $17,000 and $16,500 for 2012 and 2011, respectively, not including catch-up contributions available to eligible employees as outlined by the Internal Revenue Service.
The company matches 40% of the employees eligible contribution.
Employer contributions do not vest for up to two years of service, 50% after two years of service and 100% after three years of service.
Employees are considered to have completed one year of service for the purposes of vesting upon the completion of 1,000 hours of service at any time during a plan year.
Employer contributions to the plan for the year ended 31 December 2012 were $2,020,000 2011: $1,357,000.
Arab Pharmaceutical Manufacturing Company Jordan: The Group currently has an employee saving plan wherein the employees contribute at 10%, and the company at 15% of basic salary.
Employees are entitled to 100% of the company contributions after three years of employment with the company.
The Groups contributions for the year ended 31 December 2012 were $708,000 2011: $600,000.
The assets of the plans are held separately from those of the Group.
The only obligation of the Group with respect to the retirement benefit plans is to make specified contributions.
SUBSEQUENT EVENTS On 9 January 2013, Hikma announced that is has agreed to acquire the Egyptian Company for Pharmaceuticals & Chemical Industries EPCI : the deal was completed on 22 January 2013.
Hikma paid a cash consideration of $18,500,000 and deferred consideration of $2,000,000.
The main purpose of the acquisition was to strengthen Hikmas position in the large and fast growing Egyptian market.
Due to the timing of the acquisition, Purchase Price Allocation has not yet been performed.
156 HIKMA PHARMACEUTICALS PLC ANNUAL REPORT 2012
